The Pennsylvania Supreme Court on Thursday probed into questions about what level of public awareness regarding the dangers of a widely used pharmaceutical can sufficiently put potential plaintiffs on notice to investigate their claims.

According to an attorney representing two men alleging to have been injured by the antipsychotic drug Risperdal, the level of public awareness needs to reach as far as coverage in small-town newspapers.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]